

Estimate change	↔↔
TP change	↔↔
Rating change	↔

Motilal Oswal values your support in the EXTEL POLL 2025 for India Research, Sales, Corporate Access and Trading team. We request your ballot.

EXTEL POLL  
2025



Bloomberg		DN IN
Equity Shares (m)		136
M.Cap.(INRb)/(USDb)		237.5 / 2.7
52-Week Range (INR)		2779 / 1700
1, 6, 12 Rel. Per (%)		-4/-17/-44
12M Avg Val (INR M)		540

Financials & Valuations (INR b)			
Y/E March	FY26E	FY27E	FY28E
Sales	82.6	92.1	100.0
EBITDA	10.3	13.7	15.4
PAT	6.4	8.3	8.7
EPS (INR)	47.3	61.0	63.5
EPS Gr. (%)	-7.5	29.1	4.1
BV/Sh.(INR)	435.4	487.5	541.7
Ratios			
Net D:E	0.3	0.6	0.9
RoE (%)	11.4	13.2	12.3
RoCE (%)	9.1	9.2	7.2
Payout (%)	14.7	14.7	14.7
Valuations			
P/E (x)	36.8	28.5	27.4
P/BV (x)	4.0	3.6	3.2
EV/EBITDA (x)	24.4	20.0	19.7
Div. Yield (%)	0.4	0.5	0.5
FCF Yield (%)	-2.5	-8.6	-12.0

Shareholding Pattern (%)			
As On	Sep-25	Jun-25	Sep-24
Promoter	49.3	49.3	49.2
DII	22.7	22.6	22.3
FII	6.2	6.7	6.7
Others	21.8	21.4	21.8

FII includes depository receipts

**CMP: INR1,741 TP: INR1,530 (-12%) Sell**

## Muted operating performance amid macro challenges

### Operating performance in line with estimate

- Deepak Nitrite (DN) reported a weak operating performance, with EBITDA declining 31% YoY to INR2b in 2QFY26. Gross margin contracted 440bp YoY to 27.6% and EBITDA margin contracted 390bp, driven by macro headwinds, pricing trends, and tariff developments.
- Amid a volatile geopolitical environment and shifting global trade dynamics, we expect a recovery in 2H, led by the ramp-up of new capacities, improved volumes from market seeding of new products and SKUs, and the company's strategic initiatives to pivot into non-traditional geographies and debottleneck certain capacities.
- We broadly retain our estimates for FY26/FY27/FY28 and estimate a CAGR of 6%/12%/8% in revenue/EBITDA/PAT over FY25-28E. We value the stock at 25x FY27E EPS to arrive at our TP of INR1,530. Reiterate Sell.

## Phenolics and Intermediates segments continue to face margin headwinds

- 2Q revenue declined 6% YoY to INR19b (est. INR19.3b), primarily due to a 3% and 8% decline in the Advanced Intermediates and Phenolic segments to INR5.9b/INR13.3b.
- Gross margin came in at 27.6% (down 440bp YoY), while EBITDAM stood at 10.7% (down 390bp YoY). Employee costs as a % of sales stood at 5.2% (vs. 4.8% in 2QFY25), while other expenses stood at 11.6% (vs. 12.6% in 2QFY25).
- EBITDA declined 31% YoY to INR2b (our est. INR2b), while EBIT for the Advanced Intermediates/Phenolic segments declined 47%/52% YoY to INR1.1b/INR230m.
- EBIT margins for Advanced Intermediates/Phenolic contracted 390bp/630bp to 3.9%/8.6% in 2QFY26.
- Reported PAT declined 39% YoY to INR1.2b (in line with est.), down 39% YoY.
- In 1HFY26, its revenue/EBITDA/Adj. PAT declined 10%/35%/42% to INR38b/INR4b/INR2b.

## Highlights from the management commentary

- Guidance and outlook:** The global environment remains difficult due to rising geopolitical tensions and trade barriers. While near-term conditions are challenging, the company expects 2H performance to be better, led by the ramp-up of new capacities and the launch of new products. Key projects are progressing well, with the Nitric Acid unit and Methyl isobutyl ketone (MIBK) and Methyl Isobutyl Carbino (MIBC) unit expected to be operational by 4QFY26.
- Strategic initiatives:** The company is addressing the macro headwinds by expanding into new geographies, increasing its focus on the Indian business, investing in upstream capabilities, debottlenecking capacities, and protecting wallet share. Profitability pressures are being contained through diversified energy sourcing, overhead control, and continued cost optimization.

- **Polycarbonate:** The company's fully integrated Polycarbonate complex (India's first) is progressing as planned and is targeted for commissioning in Jan-Mar'28, supported by Petronet LNG tie-ups and strong regulatory tailwinds. While upstream capacity is being built, the company is already supplying polycarbonate-based compounds to electronics and auto customers to secure early validation. This will enable a seamless, cost-efficient integration once domestic polycarbonate production comes online.
- **Product development:** The company has launched seven products developed in-house in 2Q across life sciences and effect chemicals, all of which are undergoing customer validation (typically 3-5 months) with full ramp-up expected by the end of 4QFY26 or mid-1QFY27.

### Valuation and view

- Despite capacity expansion, new projects, process optimization, and a focus on innovation and sustainability, we expect DN's performance to be weighed down by industry-wide challenges. Persistent oversupply from China and rapidly evolving geopolitical developments continue to exert pricing pressure and weigh on operational performance.
- We broadly retain our estimates for FY26/FY27/FY28 and estimate a CAGR of 6%/12%/8% in revenue/EBITDA/PAT over FY25-28E. We value the stock at 25x FY27E EPS to arrive at our TP of INR1,530. Reiterate Sell.

### Consolidated - Quarterly Snapshot


Y/E March	(INR m)												
	FY25					FY26				FY25	FY26E	FY26	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		2QE	(%)		
<b>Gross Sales</b>	<b>21,668</b>	<b>20,320</b>	<b>19,034</b>	<b>21,797</b>	<b>18,899</b>	<b>19,019</b>	<b>20,963</b>	<b>23,738</b>	<b>82,819</b>	<b>82,618</b>	<b>19,229</b>	<b>-1%</b>	
YoY Change (%)	22.5	14.3	-5.3	2.5	-12.8	-6.4	10.1	8.9	7.8	-0.2	-5.4		
<b>Total Expenditure</b>	<b>18,577</b>	<b>17,345</b>	<b>17,349</b>	<b>18,631</b>	<b>17,003</b>	<b>16,976</b>	<b>18,127</b>	<b>20,178</b>	<b>71,901</b>	<b>72,285</b>	<b>17,299</b>		
<b>Gross Margin (%)</b>	<b>30.8%</b>	<b>32.0%</b>	<b>26.8%</b>	<b>30.6%</b>	<b>28.0%</b>	<b>27.6%</b>	<b>30.7%</b>	<b>32.0%</b>	<b>30.1%</b>	<b>29.7%</b>	<b>27.5%</b>		
<b>EBITDA</b>	<b>3,092</b>	<b>2,975</b>	<b>1,685</b>	<b>3,166</b>	<b>1,896</b>	<b>2,043</b>	<b>2,836</b>	<b>3,559</b>	<b>10,918</b>	<b>10,333</b>	<b>1,930</b>	<b>6%</b>	
Margin (%)	14.3	14.6	8.9	14.5	10.0	10.7	13.5	15.0	13.2	12.5	10.0		
Depreciation	475	485	482	513	513	533	550	580	1,954	2,175	525		
Interest	58	63	61	93	81	79	107	113	275	380	102		
Other Income	188	213	210	228	246	200	225	249	839	919	237		
<b>PBT before EO expense</b>	<b>2,748</b>	<b>2,640</b>	<b>1,352</b>	<b>2,788</b>	<b>1,547</b>	<b>1,630</b>	<b>2,404</b>	<b>3,115</b>	<b>9,528</b>	<b>8,697</b>	<b>1,540</b>		
Extra-Ord expense	0	0	0	0	0	0	0	0	0	0	0		
<b>PBT</b>	<b>2,748</b>	<b>2,640</b>	<b>1,352</b>	<b>2,788</b>	<b>1,547</b>	<b>1,630</b>	<b>2,404</b>	<b>3,115</b>	<b>9,528</b>	<b>8,697</b>	<b>1,540</b>		
Tax	723	698	371	762	425	443	606	774	2,554	2,248	389		
Rate (%)	26.3	26.4	27.4	27.3	27.5	27.2	25.2	24.8	26.8	25.9	25.2		
<b>Reported PAT</b>	<b>2,025</b>	<b>1,942</b>	<b>981</b>	<b>2,025</b>	<b>1,122</b>	<b>1,187</b>	<b>1,797</b>	<b>2,341</b>	<b>6,974</b>	<b>6,448</b>	<b>1,151</b>	<b>3%</b>	
<b>Adj PAT</b>	<b>2,025</b>	<b>1,942</b>	<b>981</b>	<b>2,025</b>	<b>1,122</b>	<b>1,187</b>	<b>1,797</b>	<b>2,341</b>	<b>6,974</b>	<b>6,448</b>	<b>1,151</b>	<b>3%</b>	
YoY Change (%)	35.1	-5.3	-51.4	3.4	-44.6	-38.9	83.2	15.6	-7.3	-7.5	-40.73		
Margin (%)	9.3	9.6	5.2	9.3	5.9	6.2	8.6	9.9	8.4	7.8	6.0		

### Exhibit 1: Change in estimates

Particulars	Actual/ Revised			Previous			Change (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue (INR m)	82,618	92,138	1,00,003	82,828	92,325	1,00,200	0%	0%	0%
EBITDA (INR m)	10,333	13,730	15,432	10,221	13,674	15,370	1%	0%	0%
PAT (INR m)	6,448	8,322	8,665	6,539	8,409	8,738	-1%	-1%	-1%
EPS (INR)	47.3	61.0	63.5	47.9	61.7	64.1	-1%	-1%	-1%


## 2QFY26 in charts

**Exhibit 2: Contribution of Phenolics to total revenue**  
declined to 69% in 2QFY26 from 70% in 1QFY25




Source: Company, MOFSL

**Exhibit 3: EBIT mix trend**




Source: Company, MOFSL

**Exhibit 4: Sales down 6% YoY**




Source: Company, MOFSL

**Exhibit 5: Margin trends**




Source: Company, MOFSL

**Exhibit 6: EBITDA trend**




Source: Company, MOFSL

**Exhibit 7: Reported PAT was down 39% YoY**




Source: Company, MOFSL


**Exhibit 8: Revenue from AI declined 3% YoY**




**Exhibit 9: AI EBITM trend**



**Exhibit 10: Revenue from DPL declined 8% YoY...**



**Exhibit 11: ...with EBIT margin at 9%**





## Earnings concall highlights

### Operational highlights:

- The marginal sequential revenue increase was driven by improved performance in the Phenolics segment, supported by lower feedstock prices, higher volumes, and a better product mix.
- However, YoY performance weakened due to global tariff actions in the US, underpriced Chinese imports, and softer realizations in several Advanced Intermediates products.
- EBITDA improvement on a sequential basis was driven by cost optimization measures, including lower energy costs, overhead rationalization, and improved production throughput.
- Profitability remained under pressure, largely due to weaker pricing in the Advanced Intermediates business.
- Aggressive cost optimization measures across power and fuel expenses, along with the rationalization of overheads, helped improve EBITDA on a QoQ basis.
- The company maintained stable volumes in Advanced Intermediates despite pricing challenges, supported by interventions such as focusing on market share protection, entering non-traditional geographies, and securing upstream feedstock availability.

### Advanced Intermediates

- The segment reported revenue of INR5.88b, compared to INR6.05b in 1QFY26 and INR6.06b in 2QFY25.
- EBIT weakness was driven by US tariff actions and sustained inflow of Chinese products at lower prices.
- Despite this, the company maintained its volumes and wallet share. Input security is expected to improve once the Nitric Acid plant becomes fully operational in 4QFY26.
- Business was impacted by the direct and indirect impact of US tariff actions, along with the continued influx of underpriced Chinese products, which remains a major constraint on a broader sectoral rebound.
- The company drove interventions to increase volumes and maintain market share, thereby delivering largely stable revenue.
- While sustained pressure on realizations impacted profitability in the AI segment, multiple remedial measures and cost optimization actions were undertaken to partly mitigate the impact.

### Phenolic

- The Phenolic segment recorded revenue of INR13.33b vs INR13.04b in 1QFY26, showing sequential growth driven by higher throughput and a favorable product mix.
- The segment also benefited from continuous variable cost optimization and deeper integration across the value chain.
- Stable domestic demand enabled the company to maximize the benefits of its deeply integrated manufacturing, resulting in continuous variable cost optimization.
- The company expanded its market share in the Phenolics segment.
- Additionally, the Phenolics business registered the highest quarterly production and sales of IPA in 2Q.

### **Polycarbonate:**

- The company has planned investments in a large-scale complex that will house India's first integrated Polycarbonate project, marking a significant step toward achieving self-reliance and increasing value addition within the country.
- This project is supported by long-term feedstock supply arrangements with Petronet LNG and benefits from strong policy support under the Atmanirbhar Bharat initiative.
- Discussions are currently at an advanced stage regarding the supply of certain utilities as part of the integrated facility.
- The company's first priority is to ensure that polycarbonate can be produced in the most cost-efficient manner. However, since this is a large-scale project and will take a few years to complete, the company has simultaneously taken steps to move downstream.
- In the interim, the company has begun establishing its presence in the customers' ecosystem by offering compounded products that use polycarbonate as the base material.
- Once these compounded products are accepted and validated by customers in segments such as electronics, mobile devices, and automotive components, it will effectively position polycarbonate manufacturing as a natural upstream integration, even though the decision to develop it was taken first.

### **Macro environment:**

- The operating environment remains complex and challenging as the company enters FY26.
- Compared to the previous year, conditions have deteriorated meaningfully, with US tariffs, dumping intensity, and underpricing now far more severe.
- The company has countered these pressures by expanding into non-traditional geographies and proactively engaging with customers to protect market share and maintain volumes.
- The global operating environment remains strained due to rising geopolitical tensions and increasing trade barriers
- While near-term conditions are challenging, the company expects performance to improve in H2 with the ramp-up of new capacities and initial volumes from new products and SKUs, with additional upside if US tariffs ease.

### **Outlook**

- A strong pipeline of upstream products, including Nitric Acid, and downstream products, such as MIBK and MIBC, is set to become operational over the next few quarters.
- The company is making rapid progress on its large CAPEX program, with new Phenol, Acetone, and IPA capacities supporting full integration toward PC resin production.
- Management expects a better trajectory for select agchem intermediates in 2H, with further upside possible if US tariffs ease.
- The Nitric Acid plant, expected to be fully operational by 4Q, will ensure reliable input supply and support margin improvement.
- A new world-class R&D center will drive innovation and product development.
- Backward integration for nitration products and the expansion of existing product lines remain key growth drivers.
- Performance is expected to improve on the back of higher agrochemical intermediate volumes from Europe and other regions.

Additional contribution is anticipated from debottlenecked capacities and improved value-capture across the integrated chain.

### **Product development**


- The company launched seven new products in 2Q, all developed in-house without external technology licenses. These include life-science products and effect chemicals used in polymers, flame retardants, and mining applications.
- These products are currently in customer validation cycles of 3–5 months, with full commercial ramp-up expected by end-4Q or mid-1Q. Early feedback indicates that product specifications exceed market standards.
- In the polymer compounding business, validation cycles can extend up to 18 months. The company has commissioned a pilot facility at Savli and is in discussions with potential strategic partners.

### **Others**

- The company has secured supply arrangements similar to those for other key raw materials, enabling it to source ammonia both domestically and through imports.
- It plans to significantly increase internal consumption of nitric acid, with the new plant expected to operate at full capacity.
- The Oman facility is expected to take around 24 months from 2QFY26 to reach commercialization.
- Chinese dumping remains a major challenge, particularly in products like sodium nitrite and certain nitro aromatics, where pricing pressure is substantial.
- The company has planned a capex outlay of INR15b for FY26.


## Financial story in charts

**Exhibit 12: Revenue contribution from Phenol to remain higher...**




Source: MOFSL

**Exhibit 13: ...with a focus on the domestic market as a play on import substitution**




Source: Company, MOFSL

**Exhibit 14: Segmental EBIT breakdown of DN**




Source: Company, MOFSL

**Exhibit 15: EBIT margin**




Source: Company, MOFSL

**Exhibit 16: EBITDA margin to normalize from FY22 levels**



Source: Company, MOFSL

**Exhibit 17: Expect ~8% PAT CAGR over FY25-28**



Source: Company, MOFSL

## Financials and valuations

Consolidated - Income Statement								
Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	(INR m) FY28E
<b>Total Income from Operations</b>	<b>43,598</b>	<b>68,022</b>	<b>79,721</b>	<b>76,818</b>	<b>82,819</b>	<b>82,618</b>	<b>92,138</b>	<b>1,00,003</b>
Change (%)	3.1	56.0	17.2	-3.6	7.8	-0.2	11.5	8.5
<b>Gross Margin (%)</b>	<b>48.1</b>	<b>39.5</b>	<b>32.9</b>	<b>31.8</b>	<b>30.1</b>	<b>29.7</b>	<b>31.1</b>	<b>31.7</b>
<b>EBITDA</b>	<b>12,470</b>	<b>16,036</b>	<b>12,894</b>	<b>11,233</b>	<b>10,918</b>	<b>10,333</b>	<b>13,730</b>	<b>15,432</b>
Margin (%)	28.6	23.6	16.2	14.6	13.2	12.5	14.9	15.4
Depreciation	1,526	1,777	1,663	1,657	1,954	2,175	3,173	4,471
<b>EBIT</b>	<b>10,944</b>	<b>14,259</b>	<b>11,231</b>	<b>9,576</b>	<b>8,964</b>	<b>8,158</b>	<b>10,557</b>	<b>10,960</b>
Int. and Finance Charges	742	340	248	118	275	380	449	481
Other Income	215	426	476	761	839	919	1,014	1,100
<b>PBT bef. EO Exp.</b>	<b>10,417</b>	<b>14,345</b>	<b>11,459</b>	<b>10,219</b>	<b>9,528</b>	<b>8,697</b>	<b>11,121</b>	<b>11,579</b>
EO Items	0	0	0	798	0	0	0	0
<b>PBT after EO Exp.</b>	<b>10,417</b>	<b>14,345</b>	<b>11,459</b>	<b>11,017</b>	<b>9,528</b>	<b>8,697</b>	<b>11,121</b>	<b>11,579</b>
Total Tax	2,659	3,678	2,939	2,908	2,554	2,248	2,799	2,915
Tax Rate (%)	25.5	25.6	25.6	26.4	26.8	25.9	25.2	25.2
Minority Interest	-	-	-	0	-	-	-	-
<b>Reported PAT</b>	<b>7,758</b>	<b>10,666</b>	<b>8,520</b>	<b>8,109</b>	<b>6,974</b>	<b>6,448</b>	<b>8,322</b>	<b>8,665</b>
<b>Adjusted PAT</b>	<b>7,758</b>	<b>10,666</b>	<b>8,520</b>	<b>7,522</b>	<b>6,974</b>	<b>6,448</b>	<b>8,322</b>	<b>8,665</b>
Change (%)	27.0	37.5	-20.1	-11.7	-7.3	-7.5	29.1	4.1
Margin (%)	17.8	15.7	10.7	9.8	8.4	7.8	9.0	8.7

Consolidated - Balance Sheet								
Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	(INR m) FY28E
Equity Share Capital	273	273	273	273	273	273	273	273
Total Reserves	23,194	33,112	40,627	47,693	53,614	59,116	66,218	73,611
<b>Net Worth</b>	<b>23,467</b>	<b>33,384</b>	<b>40,900</b>	<b>47,966</b>	<b>53,887</b>	<b>59,389</b>	<b>66,490</b>	<b>73,884</b>
Minority Interest	-	-	-	261	360	360	360	360
Total Loans	5,775	3,007	545	2,170	11,705	18,728	38,462	68,611
Deferred Tax Liabilities	1,078	1,229	1,566	1,736	2,128	2,128	2,128	2,128
<b>Capital Employed</b>	<b>30,320</b>	<b>37,620</b>	<b>43,011</b>	<b>52,133</b>	<b>68,080</b>	<b>80,605</b>	<b>1,07,440</b>	<b>1,44,982</b>
Gross Block	22,441	25,263	26,523	31,690	35,262	37,262	39,262	41,262
Less: Accum. Deprn.	3,666	5,443	7,106	8,763	10,717	12,892	16,064	20,536
<b>Net Fixed Assets</b>	<b>18,774</b>	<b>19,820</b>	<b>19,416</b>	<b>22,927</b>	<b>24,546</b>	<b>24,371</b>	<b>23,198</b>	<b>20,727</b>
Goodwill on Consolidation	-	-	-	-	27	27	27	27
Capital WIP	2,068	1,037	3,008	7,735	16,491	29,491	57,859	96,227
<b>Total Investments</b>	<b>1,893</b>	<b>4,390</b>	<b>3,794</b>	<b>1,219</b>	<b>5,109</b>	<b>5,109</b>	<b>5,109</b>	<b>5,109</b>
<b>Curr. Assets, Loans, and Adv.</b>	<b>12,868</b>	<b>19,057</b>	<b>25,069</b>	<b>29,081</b>	<b>31,004</b>	<b>30,723</b>	<b>31,253</b>	<b>33,714</b>
Inventory	3,827	5,846	8,931	7,599	9,264	9,313	10,102	10,896
Account Receivables	7,563	11,291	13,095	12,984	12,738	12,707	14,171	15,381
Cash and Bank Balance	334	418	400	4,655	4,066	3,778	1,500	1,500
Loans and Advances	1,144	1,503	2,644	3,844	4,937	4,925	5,479	5,937
<b>Curr. Liability and Prov.</b>	<b>5,283</b>	<b>6,684</b>	<b>8,277</b>	<b>8,829</b>	<b>9,097</b>	<b>9,115</b>	<b>10,005</b>	<b>10,821</b>
Account Payables	4,367	5,117	6,618	5,823	5,217	5,245	5,690	6,137
Other Current Liabilities	640	1,272	1,216	2,476	3,259	3,251	3,625	3,935
Provisions	276	296	443	531	620	619	690	749
<b>Net Current Assets</b>	<b>7,585</b>	<b>12,373</b>	<b>16,792</b>	<b>20,252</b>	<b>21,908</b>	<b>21,608</b>	<b>21,247</b>	<b>22,893</b>
<b>Appl. of Funds</b>	<b>30,320</b>	<b>37,620</b>	<b>43,011</b>	<b>52,133</b>	<b>68,080</b>	<b>80,605</b>	<b>1,07,440</b>	<b>1,44,982</b>

## Financials and valuations

### Ratios

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
<b>Basic (INR)</b>								
EPS	<b>56.9</b>	<b>78.2</b>	<b>62.5</b>	<b>55.1</b>	<b>51.1</b>	<b>47.3</b>	<b>61.0</b>	<b>63.5</b>
EPS Growth (%)	27%	37%	-20%	-12%	-7%	-8%	29%	4%
Cash EPS	68.1	91.2	74.7	67.3	65.5	63.2	84.3	96.3
BV/Share	172.0	244.8	299.9	351.7	395.1	435.4	487.5	541.7
DPS	5.5	7.0	7.5	7.5	7.5	6.9	9.0	9.3
Payout (%)	9.7	9.0	12.0	12.6	14.7	14.7	14.7	14.7
<b>Valuation (x)</b>								
P/E	30.6	22.3	27.9	31.6	34.1	36.8	28.5	27.4
Cash P/E	25.6	19.1	23.3	25.9	26.6	27.5	20.7	18.1
P/BV	10.1	7.1	5.8	5.0	4.4	4.0	3.6	3.2
EV/Sales	5.6	3.5	3.0	3.1	3.0	3.1	3.0	3.0
EV/EBITDA	19.5	15.0	18.4	20.9	22.5	24.4	20.0	19.7
Dividend Yield (%)	0.3	0.4	0.4	0.4	0.4	0.4	0.5	0.5
FCF per share	57.8	46.8	21.3	8.0	-36.2	-43.9	-149.1	-208.2
<b>Return Ratios (%)</b>								
RoE	39.6	37.5	22.9	16.9	13.7	11.4	13.2	12.3
RoCE	29.1	32.1	21.6	16.0	11.9	9.1	9.2	7.2
RoIC	32.1	36.7	24.7	19.0	16.2	14.3	18.5	19.3
<b>Working Capital Ratios</b>								
Fixed Asset Turnover (x)	2.4	3.5	4.1	3.6	3.5	3.4	3.9	4.6
Asset Turnover (x)	1.4	1.8	1.9	1.5	1.2	1.0	0.9	0.7
Inventory (Days)	32	31	41	36	41	41	40	40
Debtor (Days)	63	61	60	62	56	56	56	56
Creditor (Days)	37	27	30	28	23	23	23	22
<b>Leverage Ratio (x)</b>								
Current Ratio	2.4	2.9	3.0	3.3	3.4	3.4	3.1	3.1
Interest Coverage Ratio	14.7	41.9	45.3	80.9	32.6	21.4	23.5	22.8
Net Debt/Equity ratio	0.2	0.1	0.0	-0.1	0.1	0.3	0.6	0.9

### Consolidated - Cash Flow Statement

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
OP/(Loss) before Tax	10,417	14,345	11,459	11,017	9,528	8,697	11,121	11,579
Depreciation	1,526	1,777	1,663	1,657	1,954	2,175	3,173	4,471
Others	852	295	63	-509	-285	380	449	481
Direct Taxes Paid	-2,365	-3,535	-2,600	-2,665	-2,152	-2,248	-2,799	-2,915
(Inc.)/Dec. in WC	-412	-4,643	-4,085	-720	-2,798	12	-1,917	-1,646
<b>CF from Operations</b>	<b>10,019</b>	<b>8,239</b>	<b>6,499</b>	<b>8,781</b>	<b>6,247</b>	<b>9,015</b>	<b>10,027</b>	<b>11,971</b>
(Inc.)/Dec. in FA	-2,140	-1,862	-3,599	-7,685	-11,191	-15,000	-30,368	-40,368
<b>Free Cash Flow</b>	<b>7,879</b>	<b>6,377</b>	<b>2,900</b>	<b>1,096</b>	<b>-4,944</b>	<b>-5,985</b>	<b>-20,341</b>	<b>-28,397</b>
Change in Investments	-1,854	-2,401	816	427	-4,059	0	0	0
Others	33	22	22	40	337	0	0	0
<b>CF from Investments</b>	<b>-3,961</b>	<b>-4,241</b>	<b>-2,761</b>	<b>-7,218</b>	<b>-14,913</b>	<b>-15,000</b>	<b>-30,368</b>	<b>-40,368</b>
Issue of Shares	0	0	0	0	102	0	0	0
Inc./(Dec.) in Debt	-5,246	-2,812	-2,523	1,625	9,277	7,023	19,733	30,149
Interest Paid	-736	-320	-233	-98	-194	-380	-449	-481
Dividend Paid	-4	-750	-955	-1,023	-1,023	-946	-1,221	-1,271
Others	-5	24	120	-68	-100	0	0	0
<b>CF from Fin. Activity</b>	<b>-5,990</b>	<b>-3,858</b>	<b>-3,591</b>	<b>435</b>	<b>8,062</b>	<b>5,697</b>	<b>18,063</b>	<b>28,397</b>
<b>Inc./Dec. in Cash</b>	<b>68</b>	<b>139</b>	<b>148</b>	<b>1,998</b>	<b>-605</b>	<b>-288</b>	<b>-2,278</b>	<b>0</b>
Opening Balance	22	90	229	377	2,380	1,795	1,507	-771
<b>Closing Balance</b>	<b>90</b>	<b>229</b>	<b>377</b>	<b>2,380</b>	<b>1,795</b>	<b>1,507</b>	<b>-771</b>	<b>-771</b>

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations). Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/ListOf%20of%20Associate%20companies.pdf> MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement. The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).  
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).
6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:  
financial interest in the subject company

- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

**Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

**Terms & Conditions:**

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

**Disclaimer:**

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; [www.motilaloswal.com](http://www.motilaloswal.com).

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	<a href="mailto:query@motilaloswal.com">query@motilaloswal.com</a>
Ms. Kumud Upadhyay	022 40548082	<a href="mailto:servicehead@motilaloswal.com">servicehead@motilaloswal.com</a>
Mr. Ajay Menon	022 40548083	<a href="mailto:am@motilaloswal.com">am@motilaloswal.com</a>

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to [query@motilaloswal.com](mailto:query@motilaloswal.com). In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com), for DP to [dpgrivances@motilaloswal.com](mailto:dpgrivances@motilaloswal.com).